CapNostics, LLC.

CapNostics, LLC is a Medical Device company featuring the EsophaCap® swallawable non-endoscopic specimen collection for use with approved lab tests for the early detection of Barrett’s Esophagus and other Upper GI diseases such as cancer and H-pylori.

With the recent developments in Genome Sequencing, several corporations and medical institutions have developed Biomarker Test Kits to detect diseases of the esophagus without requiring the use of invasive and uncomfortable endoscopic techniques. The problem is that they do not have efficient non-endoscopic (non-invasive) methods of obtaining cellular specimens from patents.

We expect to penetrate and convert a substantial portion of endoscopic market currently used for screening patients who have GERDs (est. 30 million in USA.) and other upper GI conditions (est. 50 Million is USA). The second huge market is that of diagnosis of Helicobacter pylori (H. pylori) a Gram‐negative, microaerophilic bacterium found in the stomach. H.pylori is commonly present in patients with chronic gastritis and gastric ulcers. It is also linked to the development of duodenal ulcers and stomach cancer. More than 50% of the world’s population harbor H. pylori in their upper gastrointestinal tract. Physicians must be able to diagnose H.pylori in order to prescribe the proper medications.

Medical Cost Savings: The average endoscopic procedure costs $2700 in the USA. Our product together with the Biomarker test kits is a low cost, quick and easy alternative and we hope to have its use become as routine as Pap-smears are today.

Company’s Keywords:

healthcare, medical devices, bioinformatics, information technology, medical, health care, nonendoscopic specimen retrieval, barretts esophagus, pathology, hpylori